Eosinophils in cancer: Favourable or unfavourable?

Current Medicinal Chemistry

Volumn 23, Issue 7, 2016, Pages 650-666

  Sakkal, Samy ^a   Miller, Sarah ^a   Apostolopoulos, Vasso ^a   Nurgali, Kulmira ^a  

^a VICTORIA UNIVERSITY   (Australia)

Author keywords

Cancer; Cancer prognosis; Eosinophilia; Eosinophils

Indexed keywords

CHEMOKINE; CYTOKINE; EOSINOPHIL CATIONIC PROTEIN; EOSINOPHIL PEROXIDASE; EOSINOPHIL PROTEIN X; GROWTH FACTOR; LIPID;

ALLERGY; ANTIGEN PRESENTING CELL; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CARCINOGENESIS; CELL INFILTRATION; COLORECTAL CANCER; EOSINOPHIL; EOSINOPHILIA; HELMINTHIASIS; HODGKIN DISEASE; HUMAN; IMMUNE RESPONSE; INFLAMMATION; MOUTH SQUAMOUS CELL CARCINOMA; NEOPLASM; NONHUMAN; OVARY CANCER; PROSTATE CANCER; TUMOR GROWTH; TUMOR IMMUNITY; UTERINE CERVIX CANCER; ANIMAL; IMMUNOLOGY; PATHOLOGY;

ANIMALS; EOSINOPHILS; HUMANS; NEOPLASMS;

EID: 84964445526     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867323666160119094313     Document Type: Article

References (145)

1. Gleich, G.J. Mechanisms of eosinophil-associated inflammation. J. Allergy Clin. Immunol., 2000, 105(4), 651-663.
2. Jacobsen, E.A.; Taranova, A.G.; Lee, N.A.; Lee, J.J. Eosinophils: singularly destructive effector cells or purveyors of immunoregulation? J. Allergy Clin. Immunol., 2007, 119(6), 1313-1320.
3. Munitz, A.; Levi-Schaffer, F. Eosinophils:'new'roles for 'old'cells. Allergy, 2004, 59(3), 268-275.
4. Rothenberg, M.E.; Mishra, A.; Brandt, E.B.; Hogan, S.P. Gastrointestinal eosinophils. Immunol. Rev., 2001, 179(1), 139-155.
5. Kato, M.; Kephart, G.M.; Talley, N.J.; Wagner, J.M.; Sarr, M.G.; Bonno, M.; McGovern, T.W.; Gleich, G.J. Eosinophil infiltration and degranulation in normal human tissue. Anat. Rec., 1998, 252(3), 418-425.
6. Akuthota, P.; Wang, H.; Spencer, L.; Weller, P. Immunoregulatory roles of eosinophils: a new look at a familiar cell. Clin. Exp. Allergy, 2008, 38(8), 1254-1263.
7. Akuthota, P.; Wang, H.; Weller, P.F. Eosinophils as antigen-presenting cells in allergic upper airway disease. Curr. Opin. Allergy Clin. Immunol., 2010, 10, (1), 14.
8. Tamura, N.; Ishii, N.; Nakazawa, M.; Nagoya, M.; Yoshinari, M.; Amano, T.; Nakazima, H.; Minami, M. Requirement of CD80 and CD86 molecules for antigen presentation by eosinophils. Scand. J. Immunol., 1996, 44(3), 229-238.
9. Hogan, S.P.; Rosenberg, H.F.; Moqbel, R.; Phipps, S.; Foster, P.S.; Lacy, P.; Kay, A.B.; Rothenberg, M.E. Eosinophils: biological properties and role in health and disease. Clin. Exp. Allergy, 2008, 38(5), 709-750.
10. Gatault, S.; Legrand, F.; Delbeke, M.; Loiseau, S.; Capron, M. Involvement of eosinophils in the anti-tumor response. Cancer Immunol. Immunother., 2012, 61(9), 1527-1534.
11. Ellyard, J.; Simson, L.; Parish, C. Th2-mediated antitumour immunity: friend or foe? Tissue Antigens, 2007, 70(1), 1-11.
12. Rothenberg, M.E.; Hogan, S.P. The eosinophil. Ann. Rev. Immunol., 2006, 24, 147-174.
13. Glimelius, I.; Rubin, J.; Fischer, M.; Molin, D.; Amini, R.-M.; Venge, P.; Enblad, G. Effect of eosinophil cationic protein (ECP) on Hodgkin lymphoma cell lines. Exp. Hematol., 2011, 39(8), 850-858.
14. De Lima, P.O.; Dos Santos, F.V.; Oliveira, D.T.; De Figueiredo, R.C.; Pereira, M.C. Effect of eosinophil cationic protein on human oral squamous carcinoma cell viability. Mol. Clin. Oncol., 2015, 3(2), 353-356.
15. Lose, G.; Frandsen, B. Eosinophil cationic protein in urine in patients with urinary bladder tumors. Urol. Res., 1989, 17(5), 295-297.
16. Trulson, A.; Nilsson, S.; Venge, P. The eosinophil granule proteins in serum, but not the oxidative metabolism of the blood eosinophils, are increased in cancer. Br. J. Haematol., 1997, 98(2), 312-314.
17. Temkin, V.; Aingorn, H.; Puxeddu, I.; Goldshmidt, O.; Zcharia, E.; Gleich, G.J.; Vlodavsky, I.; Levi-Schaffer, F. Eosinophil major basic protein: first identified natural heparanase-inhibiting protein. J. Allergy Clin. Immunol., 2004, 113(4), 703-709.
18. Specht, S.; Saeftel, M.; Arndt, M.; Endl, E.; Dubben, B.; Lee, N.A.; Lee, J.J.; Hoerauf, A. Lack of eosinophil peroxidase or major basic protein impairs defense against murine filarial infection. Infect. Immun., 2006, 74(9), 5236-5243.
19. Klion, A.D.; Nutman, T.B. The role of eosinophils in host defense against helminth parasites. J. Allergy Clin. Immunol., 2004, 113(1), 30-37.
20. Butterfield, J.; Kephart, G.; Banks, P.; Gleich, G. Extracellular deposition of eosinophil granule major basic protein in lymph nodes of patients with Hodgkin's disease. Blood, 1986, 68(6), 1250-1256.
21. Kubo, H.; Loegering, D.A.; Adolphson, C.R.; Gleich, G.J. Cytotoxic properties of eosinophil granule major basic protein for tumor cells. Int. Arch. Allergy Immunol., 1999, 118(2-4), 426-428.
22. Liu, G.T.; Hwang, C.S.; Hsieh, C.H.; Lu, C.H.; Chang, S.L.Y.; Lee, J.C.; Huang, C.F.; Chang, H.-T. Eosinophilderived neurotoxin is elevated in patients with amyotrophic lateral sclerosis. Mediators. Inflamm., 2013, 2013, 421389.
23. Kephart, G.M.; Alexander, J.A.; Arora, A.S.; Romero, Y.; Smyrk, T.C.; Talley, N.J.; Kita, H. Marked deposition of eosinophil-derived neurotoxin in adult patients with eosinophilic esophagitis. Am. J. Gastroenterol., 2009, 105(2), 298-307.
24. Ye, B.; Skates, S.; Mok, S.C.; Horick, N.K.; Rosenberg, H.F.; Vitonis, A.; Edwards, D.; Sluss, P.; Han, W.K.; Berkowitz, R.S. Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. Clin. Cancer Res. 2006, 12(2), 432-441.
25. Dricu, A.; Sergiu-Bogdan, C.; Brismar, K.; Biberfeld, P.; Andersson, L.C. A synthetic peptide derived from the human eosinophil-derived neurotoxin induces apoptosis in Kaposi's sarcoma cells. Anticancer Res., 2004, 24(3a), 1427-1432.
26. Davis, B.P.; Rothenberg, M.E. Eosinophils and cancer. Cancer Immunol. Res., 2014, 2, (1), 1-8.
27. Wang, J.; Slungaard, A. Role of eosinophil peroxidase in host defense and disease pathology. Arch. Biochem. Biophys., 2006, 445(2), 256-260.
28. Thomas, E.L.; Bozeman, P.M.; Jefferson, M.M.; King, C.C. Oxidation of bromide by the human leukocyte enzymes myeloperoxidase and eosinophil peroxidase formation of bromamines. J. Biol. Chem., 1995, 270(7), 2906-2913.
29. Weiss, S.J.; Test, S.T.; Eckmann, C.M.; Roos, D.; Regiani, S. Brominating oxidants generated by human eosinophils. Science, 1986, 234(4773), 200-203.
30. Mayeno, A.; Curran, A.; Roberts, R.; Foote, C. Eosinophils preferentially use bromide to generate halogenating agents. J. Biol. Chem.,1989, 264(10), 5660-5668.
31. Wu, W.; Samoszuk, M.K.; Comhair, S.A.; Thomassen, M.J.; Farver, C.F.; Dweik, R.A.; Kavuru, M.S.; Erzurum, S.C.; Hazen, S.L. Eosinophils generate brominating oxidants in allergen-induced asthma. J. Clin. Invest. 2000, 105(10), 1455.
32. Samoszuk, M.; Nathwani, B.; Lukes, R. Extensive deposition of eosinophil peroxidase in Hodgkin's and non-Hodgkin's lymphomas. Am. J. Pathol., 1986, 125(3), 426.
33. Samoszuk, M.K.; Nguyen, V.; Gluzman, I.; Pham, J.H. Occult deposition of eosinophil peroxidase in a subset of human breast carcinomas. Am. J. Pathol., 1996, 148(3), 701.
34. Bandeira-Melo, C.; Bozza, P.T.; Weller, P.F. The cellular biology of eosinophil eicosanoid formation and function. J. Allergy Clin. Immunol., 2002, 109(3), 393-400.
35. Luna-Gomes, T.; Bozza, P.T.; Bandeira-Melo, C. Eosinophil recruitment and activation: the role of lipid mediators. Front. Pharmacol., 2013, 4, 27.
36. Smith, W.L.; Murphy, R.C. The eicosanoids: cyclooxygenase, lipoxygenase, and epoxygenase pathways. New Compr. Biochem., 2002, 36, 341-371.
37. McLemore, T.L.; Hubbard, W.C.; Litterst, C.L.; Liu, M.C.; Miller, S.; McMahon, N.A.; Eggleston, J.C.; Boyd, M.R. Profiles of prostaglandin biosynthesis in normal lung and tumor tissue from lung cancer patients. Cancer Res., 1988, 48(11), 3140-3147.
38. Rigas, B.; Goldman, I.S.; Levine, L. Altered eicosanoid levels in human colon cancer. J. Lab. Clin. Med., 1993, 122(5), 518-523.
39. Wang, D.; Dubois, R.N. Cyclooxygenase-2: a potential target in breast cancer. Semin. Oncol., 2004, 31(1 Suppl. 3), 64-73.
40. Wang, D.; Dubois, R.N. Eicosanoids and cancer. Nat. Rev. Cancer, 2010, 10(3), 181-193.
41. Sharma, J.; Mohammed, L. The role of leukotrienes in the pathophysiology of inflammatory disorders: is there a case for revisiting leukotrienes as therapeutic targets? Inflammopharmacology, 2006, 14(1-2), 10-16.
42. Hennig, R.; Ding, X.Z.; Tong, W.G.; Schneider, M.B.; Standop, J.; Friess, H.; Buchler, M.W.; Pour, P.M.; Adrian, T.E. 5-Lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. Am. J. Pathol., 2002, 161(2), 421-428.
43. Li, H.; Liu, K.; Boardman, L.A.; Zhao, Y.; Wang, L.; Sheng, Y.; Oi, N.; Limburg, P.J.; Bode, A.M.; Dong, Z. Circulating prostaglandin biosynthesis in colorectal cancer and potential clinical significance. EBioMedicine, 2015, 2(2), 165-171.
44. Sobolesky, P.M.; Halushka, P.V.; Garrett-Mayer, E.; Smith, M.T.; Moussa, O. Regulation of the tumor suppressor FOXO3 by the thromboxane-A2 receptors in urothelial cancer. PLoS One, 2014, 9(9), e107530.
45. Marginean, A.; Sharma-Walia, N. Lipoxins exert antiangiogenic and anti-inflammatory effects on Kaposi's sarcoma cells. Transl. Res., 2015, 166(2), 111-133.
46. Wang, Z.; Cheng, Q.; Tang, K.; Sun, Y.; Zhang, K.; Zhang, Y.; Luo, S.; Zhang, H.; Ye, D.; Huang, B. Lipid mediator lipoxin A4 inhibits tumor growth by targeting IL-10-producing regulatory B (Breg) cells. Cancer Lett., 2015, 364(2), 118-124.
47. Balkwill, F.R.; Mantovani, A. Cancer-Related Inflammation: Common Themes and Therapeutic Opportunities. In: Seminars in Cancer Biology; Elsevier: USA, 2012; Vol. 22, pp. 33-40.
48. Elovic, A.; Wong, D.T.; Weller, P.F.; Matossian, K.; Galli, S.J. Expression of transforming growth factors-α and β1 messenger RNA and product by eosinophils in nasal polyps. J. Allergy Clin. Immunol., 1994, 93(5), 864-869.
49. Rothenberg, M.E.; Hogan, S.P. The eosinophil. Immunology, 2006, 24(1), 147.
50. Hogan, S.P. Functional role of eosinophils in gastrointestinal inflammation. Immunol. Allergy Clin. North Am., 2009, 29(1), 129-140.
51. Carretero, R.; Sektioglu, I.M.; Garbi, N.; Salgado, O.C.; Beckhove, P.; Hammerling, G.J. Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. Nat. Immunol., 2015, 16(6), 609-617.
52. Davoine, F.; Lacy, P. Eosinophil cytokines, chemokines, and growth factors: emerging roles in immunity. Front. Immunol., 2014, 5, 570.
53. Jose, P.; Griffiths-Johnson, D.; Collins, P.; Walsh, D.; Moqbel, R.; Totty, N.; Truong, O.; Hsuan, J.; Williams, T. Eotaxin: a potent eosinophil chemoattractant cytokine detected in a guinea pig model of allergic airways inflammation. J. Exp. Med., 1994, 179(3), 881-887.
54. Rankin, S.M.; Conroy, D.M.; Williams, T.J. Eotaxin and eosinophil recruitment: implications for human disease. Mol. Med. Today, 2000, 6(1), 20-27.
55. Rothenberg, M.E.; Luster, A.D.; Leder, P. Murine eotaxin: an eosinophil chemoattractant inducible in endothelial cells and in interleukin 4-induced tumor suppression. Proc. Natl. Acad. Sci. USA., 1995, 92(19), 8960-8964.
56. Mishra, A.; Hogan, S.P.; Brandt, E.B.; Rothenberg, M.E. Peyer's patch eosinophils: identification, characterization, and regulation by mucosal allergen exposure, interleukin-5, and eotaxin. Blood, 2000, 96(4), 1538-1544.
57. Zhu, F.; Liu, P.; Li, J.; Zhang, Y. Eotaxin-1 promotes prostate cancer cell invasion via activation of the CCR3-ERK pathway and upregulation of MMP-3 expression. Oncol. Rep., 2014, 31(5), 2049-2054.
58. Levina, V.; Nolen, B.M.; Marrangoni, A.M.; Cheng, P.; Marks, J.R.; Szczepanski, M.J.; Szajnik, M.E.; Gorelik, E.; Lokshin, A.E. Role of eotaxin-1 signaling in ovarian cancer. Clin. Cancer Res., 2009, 15(8), 2647-2656.
59. Cheadle, E.J.; Riyad, K.; Subar, D.; Rothwell, D.G.; Ashton, G.; Batha, H.; Sherlock, D.J.; Hawkins, R.E.; Gilham, D.E. Eotaxin-2 and colorectal cancer: a potential target for immune therapy. Clin. Cancer Res., 2007, 13(19), 5719-5728.
60. Agarwal, M.; He, C.; Siddiqui, J.; Wei, J.T.; Macoska, J.A. CCL11 (eotaxin-1): A new diagnostic serum marker for prostate cancer. The Prostate, 2013, 73(6), 573-581.
61. Koc, U.; Cetinkaya, E.; Bostanci, E.B.; Kemik, A.S.; Tez, M.; Gomceli, I.; Akoglu, M. Diagnostic significance of serum eotaxin-1 level in gastric cancer patients. Dis. Markers, 2013, 35(5), 363-367.
62. Bochner, B.S. Siglec-8 on human eosinophils and mast cells, and Siglec-F on murine eosinophils, are functionally related inhibitory receptors. Clin. Exp. Allergy, 2009, 39(3), 317-324.
63. Apostolopoulos, V.; Thalhammer, T.; Tzakos, A.G.; Stojanovska, L. Targeting antigens to dendritic cell receptors for vaccine development. J. Drug Deliv., 2013, 2013, 869718.
64. Sheng, K.C.; Pietersz, G.A.; Wright, M.D.; Apostolopoulos, V. Dendritic cells: activation and maturation - applications for cancer immunotherapy. Curr. Med. Chem., 2005, 12(15), 1783-1800.
65. Sheng, K.C.; Wright, M.D.; Apostolopoulos, V. Inflammatory mediators hold the key to dendritic cell suppression and tumor progression. Curr. Med. Chem., 2011, 18(36), 5507-5518.
66. Kvarnhammar, A.M.; Cardell, L.O. Pattern-recognition receptors in human eosinophils. Immunology, 2012, 136(1), 11-20.
67. Hamann, J.; Koning, N.; Pouwels, W.; Ulfman, L.H.; van Eijk, M.; Stacey, M.; Lin, H.H.; Gordon, S.; Kwakkenbos, M.J. EMR1, the human homolog of F4/80, is an eosinophilspecific receptor. Eur. J. Immunol., 2007, 37(10), 2797-2802.
68. Lotfi, R.; Lotze, M.T. Eosinophils induce DC maturation, regulating immunity. J. Leukoc. Biol., 2008, 83(3), 456-460.
69. Yang, D.; Chen, Q.; Rosenberg, H.F.; Rybak, S.M.; Newton, D.L.; Wang, Z.Y.; Fu, Q.; Tchernev, V.T.; Wang, M.; Schweitzer, B.; Kingsmore, S.F.; Patel, D.D.; Oppenheim, J.J.; Howard, O.M. Human ribonuclease A superfamily members, eosinophil-derived neurotoxin and pancreatic ribonuclease, induce dendritic cell maturation and activation. J. Immunol., 2004, 173(10), 6134-6142.
70. Yang, D.; Rosenberg, H.F.; Chen, Q.; Dyer, K.D.; Kurosaka, K.; Oppenheim, J.J. Eosinophil-derived neurotoxin (EDN), an antimicrobial protein with chemotactic activities for dendritic cells. Blood, 2003, 102(9), 3396-3403.
71. Spessotto, P.; Dri, P.; Bulla, R.; Zabucchi, G.; Patriarca, P. Human eosinophil peroxidase enhances tumor necrosis factor and hydrogen peroxide release by human monocytederived macrophages. Eur. J. Immunol., 1995, 25, (5), 1366-1373.
72. Blum, J.S.; Wearsch, P.A.; Cresswell, P. Pathways of antigen processing. Ann. Rev. Immunol., 2013, 31, 443.
73. Duez, C.; Dakhama, A.; Tomkinson, A.; Marquillies, P.; Balhorn, A.; Tonnel, A.-B.; Bratton, D.L.; Gelfand, E.W. Migration and accumulation of eosinophils toward regional lymph nodes after airway allergen challenge. J. Allergy Clin. Immunol., 2004, 114(4), 820-825.
74. Shi, H.Z. Eosinophils function as antigen-presenting cells. J. Leukoc. Biol., 2004, 76(3), 520-527.
75. MacKenzie, J.R.; Mattes, J.; Dent, L.A.; Foster, P.S. Eosinophils promote allergic disease of the lung by regulating CD4+ Th2 lymphocyte function. J. Immunol., 2001, 167(6), 3146-3155.
76. van Rijt, L.S.; Vos, N.; Hijdra, D.; de Vries, V.C.; Hoogsteden, H.C.; Lambrecht, B.N. Airway eosinophils accumulate in the mediastinal lymph nodes but lack antigen-presenting potential for naive T cells. J. Immunol., 2003, 171(7), 3372-3378.
77. Chen, L.; Flies, D.B. Molecular mechanisms of T cell costimulation and co-inhibition. Nat. Rev. Immunol., 2013, 13(4), 227-242.
78. Ohkawara, Y.; Lim, K.G.; Xing, Z.; Glibetic, M.; Nakano, K.; Dolovich, J.; Croitoru, K.; Weller, P.F.; Jordana, M. CD40 expression by human peripheral blood eosinophils. J. Clin. Invest., 1996, 97(7), 1761.
79. Woerly, G.; Roger, N.; Loiseau, S.; Dombrowicz, D.; Capron, A.; Capron, M. Expression of Cd28 and Cd86 by human eosinophils and role in the secretion of type 1 cytokines (interleukin 2 and interferon γ) inhibition by immunoglobulin a complexes. J. Exp. Med., 1999, 190(4), 487-496.
80. Celestin, J.; Rotschke, O.; Falk, K.; Ramesh, N.; Jabara, H.; Strominger, J.; Geha, R.S. IL-3 induces B7. 2 (CD86) expression and costimulatory activity in human eosinophils. J. Immunol., 2001, 167(11), 6097-6104.
81. Shi, H.-Z.; Humbles, A.; Gerard, C.; Jin, Z.; Weller, P.F. Lymph node trafficking and antigen presentation by endobronchial eosinophils. J. Clin. Invest., 2000, 105(7), 945-953.
82. Yamamoto, H.; Sedgwick, J.B.; Vrtis, R.F.; Busse, W.W. The effect of transendothelial migration on eosinophil function. Am. J. Respir. Cell Mol. Biol., 2000, 23(3), 379-388.
83. Beninati, W.; Derdak, S.; Dixon, P.F.; Grider, D.J.; Strollo, D.C.; Hensley, R.E.; Lucey, D.R. Pulmonary eosinophils express HLA-DR in chronic eosinophilic pneumonia. J. Allergy Clin. Immunol., 1993, 92(3), 442-449.
84. Xie, Z.-F.; Shi, H.-Z.; Qin, X.-J.; Kang, L.-F.; Huang, C.-P.; Chen, Y.-Q. Effects of antigen presentation of eosinophils on lung Th1/Th2 imbalance. Chinese Med. J., 2005, 118(1), 6-11.
85. Padigel, U.M.; Lee, J.J.; Nolan, T.J.; Schad, G.A.; Abraham, D. Eosinophils can function as antigenpresenting cells to induce primary and secondary immune responses to Strongyloides stercoralis. Infect. Immun., 2006, 74(6), 3232-3238.
86. Garro, A.P.; Chiapello, L.S.; Baronetti, J.L.; Masih, D.T. Rat eosinophils stimulate the expansion of Cryptococcus neoformans-specific CD4(+) and CD8(+) T cells with a Thelper 1 profile. Immunology, 2011, 132(2), 174-187.
87. Piazuelo, M.B.; Camargo, M.C.; Mera, R.M.; Delgado, A.G.; Peek, Jr.R.M.; Correa, H.; Schneider, B.G.; Sicinschi, L.A.; Mora, Y.; Bravo, L.E. Eosinophils and mast cells in chronic gastritis: possible implications in carcinogenesis. Hum. Pathol., 2008, 39(9), 1360-1369.
88. Pretlow, T.P.; Keith, E.F.; Cryar, A.K.; Bartolucci, A.A.; Pitts, A.M.; Pretlow, T.G.; Kimball, P.M.; Boohaker, E.A. Eosinophil infiltration of human colonic carcinomas as a prognostic indicator. Cancer Res., 1983, 43(6), 2997-3000.
89. Cormier, S.A.; Taranova, A.G.; Bedient, C.; Nguyen, T.; Protheroe, C.; Pero, R.; Dimina, D.; Ochkur, S.I.; O'Neill, K.; Colbert, D. Pivotal Advance: eosinophil infiltration of solid tumors is an early and persistent inflammatory host response. J. Leuk. Biol., 2006, 79(6), 1131-1139.
90. Molin, D. Bystander cells and prognosis in Hodgkin lymphoma. Ups. J. Med. Sci., 2004, 109(3), 179-228.
91. Dorta, R.; Landman, G.; Kowalski, L.; Lauris, J.; Latorre, M.; Oliveira, D. Tumour-associated tissue eosinophilia as a prognostic factor in oral squamous cell carcinomas. Histopathology, 2002, 41(2), 152-157.
92. Fernandez-Acenero, M.; Galindo-Gallego, M.; Sanz, J.; Aljama, A. Prognostic influence of tumor-associated eosinophilic infiltrate in colorectal carcinoma. Cancer, 2000, 88(7), 1544-1548.
93. Fujii, M.; Yamashita, T.; Ishiguro, R.; Tashiro, M.; Kameyama, K. Significance of epidermal growth factor receptor and tumor associated tissue eosinophilia in the prognosis of patients with nasopharyngeal carcinoma. Auris. Nasus Larynx, 2002, 29(2), 175-181.
94. Nielsen, H.J.; Hansen, U.; Christensen, I.J.; Reimert, C.M.; Brunner, N.; Moesgaard, F. Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue. Am. J. Pathol., 1999, 189(4), 487-495.
95. Jain, M.; Kasetty, S.; Sudheendra, U.; Tijare, M.; Khan, S.; Desai, A. Assessment of tissue eosinophilia as a prognosticator in oral epithelial dysplasia and oral squamous cell carcinoma - an image analysis study. Pathol. Res. Int., 2014, 2014, 507512.
96. Furbert-Harris, P.; Parish-Gause, D.; Laniyan, I.; Hunter, K.A.; Okomo-Awich, J.; Vaughn, T.R.; Forrest, K.C.; Howland, C.; Abdelnaby, A.; Oredipe, O.A. Inhibition of prostate cancer cell growth by activated eosinophils. The Prostate, 2003, 57(2), 165-175.
97. Harbaum, L.; Pollheimer, M.J.; Kornprat, P.; Lindtner, R.A.; Bokemeyer, C.; Langner, C. Peritumoral eosinophils predict recurrence in colorectal cancer. Mod. Pathol., 2015, 28(3), 403-413.
98. McNeel, D.G.; Gardner, T.A.; Higano, C.S.; Kantoff, P.W.; Small, E.J.; Wener, M.H.; Sims, R.B.; DeVries, T.; Sheikh, N.A.; Dreicer, R. A transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who receive sipuleucel-T. Cancer Immunol. Res., 2014, 2(10), 988-999.
99. Samoszuk, M. Eosinophils and human cancer. Histol. Histopathol., 1997, 12(3), 807-12.
100. Keresztes, K.; Szollosi, Z.; Simon, Z.; Tarkanyi, I.; Nemes, Z.; Illes, A. Retrospective analysis of the prognostic role of tissue eosinophil and mast cells in Hodgkin's lymphoma. Pathol. Oncol. Res., 2007, 13(3), 237-242.
101. Gharabaghi, M.A.; Aghajanzadeh, P.; Zahedi, G.; Borji, R.; Derakhskan, L.; Sattarzadeh, R.; Sharaifian, R. Cardiac disease in a case of precursor B acute lymphoblastic leukaemia with eosinophilia (ALL/Eo). BMJ Case Rep., 2012, 2012, pii: bcr0404114128.
102. Helbig, G.; Soja, A.; Bartkowska-Chrobok, A.; Kyrcz-Krzemien, S. Chronic eosinophilic leukemia-not otherwise specified has a poor prognosis with unresponsiveness to conventional treatment and high risk of acute transformation. Am. J. Hematol., 2012, 87(6), 643-645.
103. Utsunomiya, A.; Ishida, T.; Inagaki, A.; Ishii, T.; Yano, H.; Komatsu, H.; Iida, S.; Yonekura, K.; Takeuchi, S.; Takatsuka, Y. Clinical significance of a blood eosinophilia in adult T-cell leukemia/lymphoma: a blood eosinophilia is a significant unfavorable prognostic factor. Leuk. Res., 2007, 31(7), 915-920.
104. Lowe, D.; Jorizzo, J.; Hutt, M. Tumour-associated eosinophilia: a review. J. Clin. Pathol., 1981, 34(12), 1343-1348.
105. Dunn, G.P.; Bruce, A.T.; Ikeda, H.; Old, L.J.; Schreiber, R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol., 2002, 3(11), 991-998.
106. Sosman, J.A.; Bartemes, K.; Offord, K.P.; Kita, H.; Fisher, S.G.; Kefer, C.; Ellis, T.A.; Fisher, R.I.; Higgins, T.J.; Gleich, G.J. Evidence for eosinophil activation in cancer patients receiving recombinant interleukin-4: effects of interleukin-4 alone and following interleukin-2 administration. Clin. Cancer Res., 1995, 1(8), 805-812.
107. Legrand, F.; Driss, V.; Delbeke, M.; Loiseau, S.; Hermann, E.; Dombrowicz, D.; Capron, M. Human eosinophils exert TNF-α and granzyme A-mediated tumoricidal activity toward colon carcinoma cells. J. Immunol., 2010, 185(12), 7443-7451.
108. Caruso, R.A.; Parisi, A.; Quattrocchi, E.; Scardigno, M.; Branca, G.; Parisi, C.; Luciano, R.; Paparo, D.; Fedele, F. Ultrastructural descriptions of heterotypic aggregation between eosinophils and tumor cells in human gastric carcinomas. Ultrastruct. Pathol., 2011, 35(4), 145-149.
109. Melief, C.J. Cancer immunotherapy by dendritic cells. Immunity, 2008, 29(3), 372-383.
110. Ethuin, F.; Gerard, B.; Benna, J.E.; Boutten, A.; Gougereot-Pocidalo, M.-A.; Jacob, L.; Chollet-Martin, S. Human neutrophils produce interferon gamma upon stimulation by interleukin-12. Lab. Invest., 2004, 84(10), 1363-1371.
111. Desjardins, M. The good fat: a link between lipid bodies and antigen cross-presentation. Immunity, 2009, 31(2), 176-178.
112. Fujimoto, T.; Ohsaki, Y.; Cheng, J.; Suzuki, M.; Shinohara, Y. Lipid droplets: a classic organelle with new outfits. Histochem. Cell Bio., 2008, 130(2), 263-279.
113. Grover, W.H.; Winkler, H.H.; Normansell, D.E. Phagocytic properties of isolated human eosinophils. J. Immunol., 1978, 121(2), 718-725.
114. Itano, A.A.; Jenkins, M.K. Antigen presentation to naive CD4 T cells in the lymph node. Nat. Immun., 2003, 4(8), 733-739.
115. Singer, J.; Jensen-Jarolim, E. IgE-based immunotherapy of cancer: challenges and chances. Allergy, 2014, 69(2), 137-149.
116. Jensen-Jarolim, E.; Achatz, G.; Turner, M.; Karagiannis, S.; Legrand, F.; Capron, M.; Penichet, M.; Rodriguez, J.; Siccardi, A.; Vangelista, L. AllergoOncology: the role of IgE-mediated allergy in cancer. Allergy, 2008, 63(10), 1255-1266.
117. Josephs, D.H.; Spicer, J.F.; Karagiannis, P.; Gould, H.J.; Karagiannis, S.N. IgE immunotherapy: a novel concept with promise for the treatment of cancer. mAbs, 2014, 6(1), 54-72.
118. Clutterbuck, E.J.; Hirst, E.; Sanderson, C.J. Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: comparison and interaction with IL-1, IL-3, IL-6, and GMCSF. Blood, 1989, 73(6), 1504-1512.
119. Fulkerson, P.C.; Rothenberg, M.E. Targeting eosinophils in allergy, inflammation and beyond. Nat. Rev. Drug Discov., 2013, 12(2), 117-129.
120. Rosenberg, S.A. Progress in human tumour immunology and immunotherapy. Nature, 2001, 411(6835), 380-384.
121. Herreros, B.; Sanchez-Aguilera, A.; Piris, M. Lymphoma microenvironment: culprit or innocent? Leukemia, 2007, 22(1), 49-58.
122. Chen, Y.Y.; Khoury, P.; Ware, J.M.; Holland-Thomas, N.C.; Stoddard, J.L.; Gurprasad, S.; Waldner, A.J.; Klion, A.D. Marked and persistent eosinophilia in the absence of clinical manifestations. J. Allergy Clin. Immunol., 2014, 133, (4), 1195-1202.
123. Tefferi, A. Blood eosinophilia: a new paradigm in disease classification, diagnosis, and treatment. Mayo Clin. Proc., 2005, 80(1), 75-83.
124. Roufosse, F.; Weller, P.F. Practical approach to the patient with hypereosinophilia. J. Allergy Clin. Immunol., 2010, 126(1), 39-44.
125. Blumenthal, K.G.; Youngster, I.; Rabideau, D.J.; Parker, R.A.; Manning, K.S.; Walensky, R.P.; Nelson, S.B. Peripheral blood eosinophilia and hypersensitivity reactions among patients receiving outpatient parenteral antibiotics. J. Allergy Clin. Immunol., 2015, 136(5), 1288-1294.
126. Smith, S.G.; Chen, R.; Kjarsgaard, M.; Huang, C.; Oliveria, J.P.; O'Byrne, P.M.; Gauvreau, G.M.; Boulet, L.P.; Lemiere, C.; Martin, J.; Nair, P.; Sehmi, R. Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia. J. Allergy Clin. Immunol., 2015.
127. Furuta, G.T.; Nieuwenhuis, E.E.; Karhausen, J.; Gleich, G.; Blumberg, R.S.; Lee, J.J.; Ackerman, S.J. Eosinophils alter colonic epithelial barrier function: role for major basic protein. Am. J. Physiol. Lung Cell Mol. Physiol., 2005, 289(5), G890-G897
128. Humphreys, R.C.; Hennighausen, L. Transforming growth factor alpha and mouse models of human breast cancer. Oncogene, 2000, 19(8), 1085-1091.
129. Kawamata, H.; Kameyama, S.; Oyasu, R. In vitro and in vivo acceleration of the neoplastic phenotype of a lowtumorigenicity rat bladder carcinoma cell line by transfected transforming growth factor-alpha. Mol. Carcinog., 1994, 9(4), 210-219.
130. Grandis, J.R.; Melhem, M.F.; Gooding, W.E.; Day, R.; Holst, V.A.; Wagener, M.M.; Drenning, S.D.; Tweardy, D.J. Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival. J. Natl. Cancer Inst., 1998, 90(11), 824-832.
131. Iihara, K.; Shiozaki, H.; Tahara, H.; Kobayashi, K.; Inoue, M.; Tamura, S.; Miyata, M.; Oka, H.; Doki, Y.; Mori, T. Prognostic significance of transforming growth factor-α in human esophageal carcinoma implication for the autocrine proliferation. Cancer, 1993, 71(10), 2902-2909.
132. Yin, J.J.; Selander, K.; Chirgwin, J.M.; Dallas, M.; Grubbs, B.G.; Wieser, R.; Massague, J.; Mundy, G.R.; Guise, T.A. TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Invest., 1999, 103(2), 197-206.
133. Becker, C.; Fantini, M.C.; Schramm, C.; Lehr, H.A.; Wirtz, S.; Nikolaev, A.; Burg, J.; Strand, S.; Kiesslich, R.; Huber, S. TGF-β suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity, 2004, 21(4), 491-501.
134. Maeda, K.; Chung, Y.S.; Ogawa, Y.; Kang, S.M.; Ogawa, M.; Sawada, T.; Sowa, M. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer, 1996, 77(5), 858-863.
135. Willett, C.G.; Boucher, Y.; Di Tomaso, E.; Duda, D.G.; Munn, L.L.; Tong, R.T.; Chung, D.C.; Sahani, D.V.; Kalva, S.P.; Kozin, S.V. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med, 2004, 10(2), 145-147.
136. Salven, P.; Ruotsalainen, T.; Mattson, K.; Joensuu, H. High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int. J. Cancer, 1998, 79(2), 144-146.
137. Park, B.K.; Zhang, H.; Zeng, Q.; Dai, J.; Keller, E.T.; Giordano, T.; Gu, K.; Shah, V.; Pei, L.; Zarbo, R.J. NF-κB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nat. Med., 2007, 13(1), 62-69.
138. Kryczek, I.; Wei, S.; Zou, L.; Altuwaijri, S.; Szeliga, W.; Kolls, J.; Chang, A.; Zou, W. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J. Immunol., 2007, 178(11), 6730-6733.
139. Michalaki, V.; Syrigos, K.; Charles, P.; Waxman, J. Serum levels of IL-6 and TNF-α correlate with clinicopathological features and patient survival in patients with prostate cancer. Br. J. Cancer, 2004, 90(12), 2312-2316.
140. Gocheva, V.; Wang, H.-W.; Gadea, B.B.; Shree, T.; Hunter, K.E.; Garfall, A.L.; Berman, T.; Joyce, J.A. IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev., 2010, 24(3), 241-255.
141. Todaro, M.; Perez Alea, M.; Scopelliti, A.; Medema, J.P.; Stassi, G. IL-4-mediated drug resistance in colon cancer stem cells. Cell Cycle, 2008, 7(3), 309-313.
142. van Haelst Pisani, C.; Kovach, J.S.; Kita, H.; Leiferman, K.M.; Gleich, G.J.; Silver, J.; Dennin, R.; Abrams, J. Administration of interleukin-2 (IL-2) results in increased plasma concentrations of IL-5 and eosinophilia in patients with cancer. Blood, 1991, 78(6), 1538-1544.
143. Mumberg, D.; Monach, P.A.; Wanderling, S.; Philip, M.; Toledano, A.Y.; Schreiber, R.D.; Schreiber, H. CD4+ T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ. Proc. Natl. Acad. Sci. USA., 1999, 96(15), 8633-8638.
144. Vlad, A.M.; Budiu, R.A.; Lenzner, D.E.; Wang, Y.; Thaller, J.A.; Colonello, K.; Crowley-Nowick, P.A.; Kelley, J.L.; Price, F.V.; Edwards, R.P. A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer. Cancer Immunol. Immunother., 2010, 59(2), 293-301.
145. van Driel, W.J.; Hogendoorn, P.C.; Jansen, F.-W.; Zwinderman, A.H.; Trimbos, J.; Fleuren, G.J. Tumorassociated eosinophilic infiltrate of cervical cancer is indicative for a less effective immune response. Hum. Pathol., 1996, 27(9), 904-911.